Adalta (ASX:1AD) announced financial results for the quarter ended 30 September 2022.

Important new data for inhaled AD-214 received.

New collaboration with GPCR Therapeutics to explore use of AD-214 in cancer.

AD-214 strategic priorities to be released, webinar to discuss week commencing 31 October 2022.

AbbVie?s US$225 million acquisition of preclinical stage DJS Antibodies highlights commercial potential of antifibrotic drugs.

R&D organisation changes.

$7.16 million cash position as at 30 September 2022 ($8.66 million as at 30 June 2022).

$1.58 million R&D Tax Incentive rebate received post quarter end.

Following the announcement the company?s share price rose 4.081%.